AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 141 min read$CYTK

Blum Robert I sold $615K of CYTK

Blum Robert I (President & CEO) sold 7,500 shares of CYTOKINETICS INC (CYTK) at $82.02 ($0.62M total) across 2 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Blum Robert I
Published Jul 14, 2026, 7:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 14, 2026, 7:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CYTK
Neutral
high confidence
Mentioned
$CYTK
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYTKNeutralLow
01

Why it matters

The CEO’s open-market sale is disclosed with execution price, share count, and confirmation of a pre-arranged 10b5-1 plan, but no new business developments are provided.

02

Market read

Primarily a sentiment/positioning datapoint; not a fundamental catalyst.

03

What to watch

Traders may over-weight insider sales; without accompanying changes in guidance, contracts, or trial updates, the signal is typically weak.

Relevance 4/10Novelty 3/10Timing: Filed 2026-07-14 after-hours; reflects 2026-07-13 sale execution.

Background

The article is an SEC Form 4 insider transaction disclosure for Cytokinetics, Inc. (CYTK).

Company-level read

Ticker impact

$CYTKNeutralHigh confidence
Context

CYTOK insider Form 4 shows CEO Robert I. Blum sold 7,500 shares on 2026-07-13 at $82.02 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect is more about sentiment than fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged Rule 10b5-1 plan, and provides no new company-specific news beyond the sale details.

Market effects

Sector

No sector read-through; this is company-specific insider trading disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • issuer
    CYTOKINETICS INC

    Company whose CEO insider sale is disclosed via SEC Form 4.

  • insider
    Blum Robert I

    President and CEO who sold 7,500 shares on 2026-07-13 under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CYTK insider trading history →

Related articles

OCT 13
$CYTKHigh

Cytokinetics Highlights Exercise Capacity, Responder Data For Aficamten In NHCM At HFSA 2026

Cytokinetics (CYTK) presented data from the ACACIA-HCM trial at the HFSA 2026 meeting, showing aficamten improved exercise performance and clinical outcomes in non-obstructive HCM patients. The drug demonstrated significant benefits in exercise capacity, symptom relief, and safety, with 53% of patients showing improvements across multiple domains. CYTK reported a Q2 2026 net loss of $198.8M and $25.3M in aficamten revenue, with cash reserves of $1.7B.

rttnews.com2 min
OCT 12
$CYTKMed

Cytokinetics presents additional aficamten data from trial

Cytokinetics (CYTK) presented additional data from its ACACIA-HCM trial at the Heart Failure Society of America Annual Scientific Meeting. Aficamten showed statistically significant improvements in exercise performance and clinical response in patients with non-obstructive hypertrophic cardiomyopathy. The company plans to submit a supplemental New Drug Application to the FDA this quarter for this indication.

uk.investing.com1 min
OCT 12
$CYTKMed

Serious heart failure events affected 4.7% taking aficamten, versus 1.2% on placebo.

Cytokinetics (CYTK) presented additional data from the ACACIA-HCM trial at the HFSA Annual Scientific Meeting. The study showed aficamten improved exercise performance and safety in non-obstructive HCM patients. Serious heart failure events occurred in 4.7% of aficamten patients vs. 1.2% on placebo. The company plans to submit a supplemental New Drug Application to the FDA this quarter.

stocktitan.net4 min